EVERSAN and Havas Health & You announced an exclusive strategic partnership agreement, inclusive of data, analytics and predictive platforms, combined with commercialization services, to offer to health and wellness clients worldwide.

W2O, a leading independent provider of analytics-driven, technology-enabled marketing and communications solutions to the healthcare sector, announced the acquisition of Discern Health.

Moderna

Shares of Moderna Inc. fell nearly 10% after the company lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma that poses a potential obstacle to Moderna’s efforts to develop next-generation vaccines, including a coronavirus vaccine.

EVERSANA announced a partnership with the Institute for Clinical and Economic Review (ICER) to advance standards for the usage of transparent, replicable and robust indirect treatment comparisons in health technology assessments.

Frost & Sullivan IDs Five New Technologies to Power Research Across Preclinical Disease Models Published: July 16, 2020 BioSpace When the CEOs of young, innovative biotech companies discuss how their […]

Light-activated CRISPR technology edits genes more precisely and faster than the more standard chemical methods, and enables “super-fast” DNA repair, according to research from Johns Hopkins University School of Medicine.

GlaxoSmithKline is diving deeper into the realm of synthetic lethality through a new partnership with Bay Area-based IDEAYA Biosciences. The two companies are exploring potential oncology treatments with emerging technology.

Pharmaceutical companies are no strangers to digital technology, either in the science that creates their products or in the business of bringing them to the people who prescribe them. As the use of digital-first experiences intensifies and the pharmaceutical industry is forced to evolve, companies will need to lean on their data and technologies in their engagement efforts to deliver elevated human experiences.

The U.S. Food and Drug Administration granted clearance for Akili’s EndeavorRx as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD).

GlaxoSmithKline inked deals earlier this year to support the development of multiple adjuvanted COVID-19 vaccine candidates and has now pledged to manufacture 1 billion doses of that efficacy-boosting system by 2021.